Increased Expression of Insulin-Like Growth Factor I is Associated with Ara-C Resistance in Leukemia
-
- Abe Shori
- Department of Rheumatology and Hematology, Tohoku University School of Medicine
-
- Funato Tadao
- Department of Laboratory Science, School of Health Sciences, Faculty of Medicines, Kyoto University
-
- Takahashi Shinichiro
- Department of Infection Control and Laboratory Diagnostics, Tohoku University School of Medicine
-
- Yokoyama Hisayuki
- Department of Rheumatology and Hematology, Tohoku University School of Medicine
-
- Yamamoto Joji
- Department of Rheumatology and Hematology, Tohoku University School of Medicine
-
- Tomiya Yasuo
- Department of Rheumatology and Hematology, Tohoku University School of Medicine
-
- Yamada-Fujiwara Minami
- Department of Rheumatology and Hematology, Tohoku University School of Medicine
-
- Ishizawa Kenichi
- Department of Rheumatology and Hematology, Tohoku University School of Medicine
-
- Kameoka Junichi
- Department of Rheumatology and Hematology, Tohoku University School of Medicine
-
- Kaku Mitsuo
- Department of Infection Control and Laboratory Diagnostics, Tohoku University School of Medicine
-
- Harigae Hideo
- Department of Rheumatology and Hematology, Tohoku University School of Medicine
-
- Sasaki Takeshi
- Department of Rheumatology and Hematology, Tohoku University School of Medicine
Search this article
Abstract
Resistance to cytosine arabinoside (Ara-C) is a major problem in the treatment of patients with acute myeloid leukemia (AML). In order to investigate the mechanisms involved in Ara-C resistance, the gene expression profile of Ara-C-resistant K562 human myeloid leukemia cells (K562/AC cells) was compared to that of Ara-C-sensitive K562 cells (K562 cells) by using a cDNA microarray platform. Correspondence analysis demonstrated that insulin-like growth factor I (IGF-I) gene was upregulated in K562/AC cells. The biological significance of IGF-I overexpression was further examined in vitro. When K562 cells were incubated with IGF-I ligand, they were protected from apoptosis induced by Ara-C. In contrast, a significant inhibition of growth and increase of apoptosis of K562/AC cells were induced by IGF-I receptor neutralizing antibody, or suramin, a nonspecific growth factor antagonist. Moreover, from the analysis of 27 AML patients, we have shown that IGF-I expression levels are higher in patients at refractory stage, after Ara-C combined chemotherapy, than those in patients at diagnosis. These results suggest that the inhibition of IGF-I and its downstream pathway is a valuable therapeutic approach to overcome Ara-C resistance in AML.
Journal
-
- The Tohoku Journal of Experimental Medicine
-
The Tohoku Journal of Experimental Medicine 209 (3), 217-228, 2006
Tohoku University Medical Press
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679216547456
-
- NII Article ID
- 10019253644
-
- NII Book ID
- AA00863920
-
- ISSN
- 13493329
- 00408727
-
- HANDLE
- 10097/52703
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- IRDB
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed